Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00458016 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT00458016 is a Phase 2 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT00458016, a Phase 2 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus
Interventions
- DRUG Placebo
- DRUG MB07803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00458016
The ClinicalTrials.gov registry entry for NCT00458016 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00458016 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00458016 about?
NCT00458016 is a clinical study titled "Safety, Tolerability, and Efficacy Study of MB07803 Administered to Patients With Type 2 Diabetes Mellitus". The purpose of this study is to collect important information regarding the safety, tolerability, and efficacy of MB07803 when administered for 28 days in patients with type 2 diabetes mellitus
What is the current status of trial NCT00458016?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2007-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00458016?
The interventions under investigation include: Placebo (DRUG), MB07803 (DRUG).
Who is sponsoring clinical trial NCT00458016?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.